Dr. Jeffrey Taub, MD
Claim this profileWayne State University/Karmanos Cancer Institute
Studies Lymphoma
Studies Head and Neck Cancers
13 reported clinical trials
55 drugs studied
Area of expertise
1Lymphoma
Stage I
Stage II
Stage IV
2Head And Neck Cancers
Stage I
Stage II
Stage IV
Affiliated Hospitals
Clinical Trials Jeffrey Taub, MD is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Selumetinib vs Carboplatin/Vincristine
for Brain Cancer
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine.
Recruiting2 awards Phase 328 criteria
More about Jeffrey Taub, MD
Clinical Trial Related7 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Jeffrey Taub, MD has experience with
- Cytarabine
- Thioguanine
- Quality-of-Life Assessment
- Selpercatinib
- Tipifarnib
- Idarubicin
Breakdown of trials Jeffrey Taub, MD has run
Lymphoma
Head and Neck Cancers
Brain Tumor
Neuroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeffrey Taub, MD specialize in?
Jeffrey Taub, MD focuses on Lymphoma and Head and Neck Cancers. In particular, much of their work with Lymphoma has involved Stage I patients, or patients who are Stage II.
Is Jeffrey Taub, MD currently recruiting for clinical trials?
Yes, Jeffrey Taub, MD is currently recruiting for 2 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Jeffrey Taub, MD has studied deeply?
Yes, Jeffrey Taub, MD has studied treatments such as Cytarabine, Thioguanine, Quality-of-Life Assessment.
What is the best way to schedule an appointment with Jeffrey Taub, MD?
Apply for one of the trials that Jeffrey Taub, MD is conducting.
What is the office address of Jeffrey Taub, MD?
The office of Jeffrey Taub, MD is located at: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan 48201 United States. This is the address for their practice at the Wayne State University/Karmanos Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.